Navigation Links
Important Progress Toward Control of Hepatitis B and C
Date:4/24/2008

Positive Tests Results for New Drugs Against Hepatitis C

Improved Screening for Hepatitis C Reflects Physicians' Optimism New Drugs Effective Against Hepatitis B, But Patient Selection Necessary

MILAN, April 25 /PRNewswire/ -- Scientists presenting at today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) reported encouraging findings regarding the potential efficacy of treatment strategies using new drugs designed to combat hepatitis B and C.

Notable progress has been made in clarifying the structure of the hepatitis C virus (HCV), leading to the development of new experimental drugs such as protease inhibitors and polymerase inhibitors, drugs that inhibit virus production. Some of these drugs have been extensively tested and some are currently in phase II trials. Phase III trials are planned. Based on results to date, it is clear that these drugs can be highly effective in combination with pegylated interferon and ribavirin. Novel anti-viral approaches at the preclinical developmental stage will also be presented.

An important trend in HCV has emerged in the past 5 years across many parts of Europe. In the past, cases of chronic hepatitis C often went undiagnosed because physicians assumed that the HCV regimen involved severe side effects and was destined to fail in most cases. Now, typically, when physicians see patients with even minor alterations of liver function tests, they then test for HCV. This is because they have been convinced that these patients can be successfully treated. Ironically, a new problem arises... According to Dr. Antonio Craxi, Professor of Gastroenterology and Internal Medicine at the University of Palermo, Italy, "Many physicians now have unreasonably optimistic expectations. Fifty percent of patients - generally those with the most severe disease -- will fail to respond to current therapy. They have more fibrosis, more advanced liver disease,
'/>"/>

SOURCE EASL - European Association for the Study of the Liver
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
2. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
3. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
4. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. EpiCept Reports Regulatory Progress on Ceplene(TM)
7. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
8. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
9. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
10. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
11. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 A victim of medical ... doctor with a history of alcohol abuse, a ... Yes on Prop 46 today, highlighting how Prop 46 will ... alcohol testing. The ad pictures a doctor ... "911-Report To ER."  Proposition 46 will enact the first law ...
(Date:10/17/2014)... , Oct. 17, 2014 The following ... Technology Policy: The Green Park Collaborative ... public and private payers, medical device and pharmaceutical ... other experts January 12, 2015 at its first ... of weight loss treatments.  Participants will discuss study ...
(Date:10/17/2014)... Conn. , Oct. 17, 2014  UBM Medica ... online community for endocrinologists and other clinicians who treat ... comprehensive coverage on effective use of insulin .  ... eventually require insulin replacement therapy – daily ... for the progressive decline in the function of pancreatic ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... 2011 What:   Investigators ... of FDA,s 510(k) regulatory pathway—through which more than 90% ... it. The study is the most comprehensive survey to ... Center for Devices and Radiological Health (CDRH) is currently ...
... SOUTH SAN FRANCISCO, Calif., May 18, 2011 Onyx ... the presentation of several studies evaluating carfilzomib, a selective, ... inhibitor, in hematological cancers at the 47th American Society ... in Chicago, IL. "The data that will ...
Cached Medicine Technology:Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 2Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 3Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 4Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 5Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 6Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 7
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... 12 HOUR for use in treating symptoms of seasonal allergic ... a combination of desloratadine 2.5 mg and pseudoephedrine sulfate, USP ... in persons above 12 years of age. The drug ... non-nasal symptoms occurring due to seasonal allergic rhinitis. Two ...
... India’s National Institute of Immunology are reported to have ... how the tuberculosis (TB) bacteria survives in the human ... and more effective medicines to combat the disease, which ... world annually. The research team led by Rajesh S. ...
... new survey has found that many British workers are not averse ... be sent in by text messages or the typical cough and ... is the widespread dissatisfaction with holiday allowance for British workers, who ... ,'Early February is a very popular time for ...
... leaders, particularly in South Asia to prohibit smoking among the ... the British Medical Journal (BMJ). The help of the Muslim ... ,The researchers analyzed data on the prevalence of smoking ... Smoking rates in each of these countries is significantly higher ...
... topic for several years, gaining momentum over the past one ... physiological responses to them. A new study, published in the ... effect of types of placebo devices Vs pills on patients ... placebos to gauge the effectiveness of novel treatment methods, but ...
... of Health said that conventional tests fail to identify smaller blood ... sign because they do not have the bulky clogs in main ... shortness of breath and are at an increased risk of a ... is very common among both men and women and causes maximum ...
Cached Medicine News:Health News:Placing a Finger on Responses to Placebo Types 2
... surface preparation is the Leica SM2500 sledge ... ,Ultramilling is often a viable alternative to ... preparation. Especially with difficult specimens, where hard ... side in one specimen block, the results ...
... The Trellis Infusion Catheter enables the physician ... physician-specified fluid, and disperse the agent by ... The Trellis is a multi-lumen catheter with ... end and infusion holes located between these ...
... The SENSAR® Acrylic IOL with OptiEdge ... performance, long-term refractive stability, and excellent handling. ... has had no reports of vacuoles; the ... internal reflections and provide 360 degrees of ...
... acrylic foldable single-piece posterior chamber lenses are ... human crystalline lens in the visual correction ... age and older. The optical portion consists ... material. These lenses have biconvex optics and ...
Medicine Products: